Official tally deems Forest proxy-fight winner; Will private equity grab PharMerica from Omnicare?;

@FiercePharma: Sanofi could kill two birds with one stone with buyout of India's Universal Medicare. 1. Emerging markets. 2. OTC brands. Story | Follow @FiercePharma

> It's official: Forest Laboratories ($FRX) shareholders chose the company's board nominees over the slate proposed by activist investor Carl Icahn, ending the proxy fight in a loss for the challengers. Release

> PharMerica ($PMC) isn't impressed by Omnicare's ($OCR) $15-per-share buyout bid; analysts figure private equity may swoop in with a higher offer. Report

> Afexa Life Sciences reaffirmed its rejection of a hostile takeover bid from Paladin Labs. Article

> Researchers didn't find a major heart risk with new psoriasis drugs, but say more study is needed to make sure. Piece

> Zacks put Onyx Pharmaceuticals on its "strong sell" list after Q2 losses came in wider than the average forecast. News

> Growing business from Chinese clients pushed ShangPharma's sales up, helping the research services firm diversify away from multinationals. Report

Biotech News

@FierceBiotech: Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful Alpharadin for prostate cancer. Item | Follow @FierceBiotech

@JohnCFierce: NIH conflict rules for researchers. Researchers have to notify at $5K, but people have to ask to see it. No public site. That's a mistake. | Follow @JohnCFierce

@RyanMFierce: Samsung entering the genomic analysis fray with cloud-based service, free pilot phase from Sept. to Nov. News | Follow @RyanMFierce

@MaureenFierce: "Unabomber Copycat" Group Threatens Nanotechnology Researchers. Piece | Follow @MaureenFierce

> Peregrine shares spike on Ph2 cancer data. Report

> Boehringer Ingelheim gets the dirt flying on $42.5M R&D facility. More

> SurModics slashes delivery tech workforce, closes plant in restructuring. Story

> Docs wary of any biosimilars that lack compelling data. Article

> NIH 's final conflict rules for researchers spur new controversy. Details

> United vows to file NDA on PAH drug after it flunks Ph3. News

Drug Delivery News

> Unilife boasts 'world's first' safety mechanism in multi-chamber syringe. More

> Alkermes stock upgrade validates drug delivery focus. News

> New nasal delivery method may offer faster, better pain relief. Report

> Drug-delivery company SurModics cuts 9% of workforce after J&J loss. Story

> Echo Therapeutics video shows pain-free skin prep. Details

> Microwaves get bacteria to open sesame. Article

Medical Device News

> Occlutech reports closing of $21.6M financing. More

> Thermo Fisher wraps up Phadia buy. Report

> Aethlon, Sarcoma Oncology Center to study hemopurifier in cancer patients. Article

> GE lays off 81 in Milwaukee. Story

> SurModics cutting 9% of workforce in realignment. News

> Medtronic sees net earnings slide 1% in Q1. Details

And Finally... New narcolepsy cases tripled in China after the swine flu pandemic, but not because of vaccines, study finds. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.